Trial Details 49 Total Sites (Page 2)

A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy

This is a global Phase III, randomized, placebo-controlled, double-blind study designed to evaluate the efficacy and safety of adjuvant treatment with atezolizumab compared with placebo in participants with MIBC who are ctDNA positive and are at high risk for recurrence following cystectomy.

São Paulo, Brazil
facility
Hospital Beneficência Portuguesa
1 facility
Recruiting
São Paulo, Brazil
facility
Hospital Alemao Oswaldo Cruz; Pesquisa Clinica
1 facility
Recruiting
Toronto, Canada
facility
Princess Margaret Cancer Center
facility
Sunnybrook Research Institute
2 facilities
Recruiting
Fortaleza, Brazil
facility
Crio - Centro Regional Integrado de Oncologia
facility
Oncocentro Serviços Medicos E Hospitalares Ltda
2 facilities
Recruiting
Curitiba, Brazil
facility
Hospital Erasto Gaertner
1 facility
Recruiting
Kharkiv, Ukraine
facility
Regional Clinical Center of Urology and Nephrology n.a. V.I. Shapoval Department of Urology #4
1 facility
Recruiting
Porto Alegre, Brazil
facility
Hospital Nossa Senhora da Conceicao
facility
Hospital Moinhos de Vento
+1 more facilities
3 facilities
Recruiting
Dnipro, Ukraine
facility
ME Dnipropetrovsk Regional Clinical Hospital n.a. I.I Mechnykov Dnipropetrovsk Regional Council
1 facility
Recruiting
Lviv, Ukraine
facility
Lviv Regional Clinical Hospital
1 facility
Recruiting
Bologna, Italy
facility
AZ.Osp S. Orsola - Malpighi-Reparto di Oncologia Medica
1 facility
Recruiting
Córdoba, Spain
facility
Hospital Universitario Reina Sofia; Servicio de Oncologia
1 facility
Recruiting
Santa Maria, Brazil
facility
Clinica Viver
1 facility
Recruiting